-
Je něco špatně v tomto záznamu ?
Expulsion of amplified MYCN from homogenously staining chromosomal regions in neuroblastoma cell lines after cultivation with cisplatin, doxorubicin, hydroxyurea, and vincristine
P. Procházka, J. Hraběta, A. Vícha, T. Eckschlager
Jazyk angličtina Země Spojené státy americké
Typ dokumentu práce podpořená grantem
- MeSH
- buněčný cyklus MeSH
- cisplatina aplikace a dávkování MeSH
- doxorubicin aplikace a dávkování MeSH
- geny myc MeSH
- hybridizace in situ fluorescenční MeSH
- hydroxymočovina aplikace a dávkování MeSH
- lidé MeSH
- nádorové buněčné linie MeSH
- neuroblastom genetika patologie MeSH
- protokoly protinádorové kombinované chemoterapie aplikace a dávkování MeSH
- vinkristin aplikace a dávkování MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- práce podpořená grantem MeSH
Amplified MYCN, common in neuroblastomas, can be detected as double minutes (dmin) or homogenously staining chromosomal regions (hsr). Expulsion of amplified MYCN has only been described in dmin. We used hydroxyurea (HU), which accelerates the expulsion of amplified genes and cytostatics (used in neuroblastoma therapy), to describe MYCN amplification changes after chemotherapy. We used IMR-32, SK-N-AS, UKF-NB-2, UKF-NB-3, UKF-NB-4, and derived sublines resistant to doxorubicin, cisplatin, and vincristine. The loss of amplified MYCN copies was investigated using comparative genomic hybridization and by fluorescent in situ hybridization. We found expulsion of amplified MYCN from hsr in UKF-NB-4 and IMR-32 cell lines, and determined the exact number of amplified MYCN copies. After the first cultivation with HU, some amplified MYCN was lost. UKF-NB-4 lost 20 copies on average, and IMR-32 lost 15 copies (P<0.001). After the second cultivation, cells without MYCN amplification were found. In comparison to sensitive cell lines, drug-resistant cell lines lost 17 copies on average. Our data show that expulsion of amplified MYCN genes is also possible from hsr and may be induced, not only by HU, but by other cytostatics as well.
- 000
- 02952naa 2200385 a 4500
- 001
- bmc11022288
- 003
- CZ-PrNML
- 005
- 20121102095241.0
- 008
- 110729s2010 xxu e Eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Procházka, Pavel. $7 xx0195988
- 245 10
- $a Expulsion of amplified MYCN from homogenously staining chromosomal regions in neuroblastoma cell lines after cultivation with cisplatin, doxorubicin, hydroxyurea, and vincristine / $c P. Procházka, J. Hraběta, A. Vícha, T. Eckschlager
- 314 __
- $a Department of Pediatric Hematology and Oncology, Charles University in Prague - 2nd Medical School, V Uvalu 84, Prague 15006, Czech Republic. proch.pavel@gmail.com
- 520 9_
- $a Amplified MYCN, common in neuroblastomas, can be detected as double minutes (dmin) or homogenously staining chromosomal regions (hsr). Expulsion of amplified MYCN has only been described in dmin. We used hydroxyurea (HU), which accelerates the expulsion of amplified genes and cytostatics (used in neuroblastoma therapy), to describe MYCN amplification changes after chemotherapy. We used IMR-32, SK-N-AS, UKF-NB-2, UKF-NB-3, UKF-NB-4, and derived sublines resistant to doxorubicin, cisplatin, and vincristine. The loss of amplified MYCN copies was investigated using comparative genomic hybridization and by fluorescent in situ hybridization. We found expulsion of amplified MYCN from hsr in UKF-NB-4 and IMR-32 cell lines, and determined the exact number of amplified MYCN copies. After the first cultivation with HU, some amplified MYCN was lost. UKF-NB-4 lost 20 copies on average, and IMR-32 lost 15 copies (P<0.001). After the second cultivation, cells without MYCN amplification were found. In comparison to sensitive cell lines, drug-resistant cell lines lost 17 copies on average. Our data show that expulsion of amplified MYCN genes is also possible from hsr and may be induced, not only by HU, but by other cytostatics as well.
- 590 __
- $a bohemika - dle Pubmed
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $7 D000971
- 650 _2
- $a buněčný cyklus $7 D002453
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a cisplatina $x aplikace a dávkování $7 D002945
- 650 _2
- $a doxorubicin $x aplikace a dávkování $7 D004317
- 650 _2
- $a geny myc $7 D016259
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hydroxymočovina $x aplikace a dávkování $7 D006918
- 650 _2
- $a hybridizace in situ fluorescenční $7 D017404
- 650 _2
- $a neuroblastom $x genetika $x patologie $7 D009447
- 650 _2
- $a vinkristin $x aplikace a dávkování $7 D014750
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Hraběta, Jan $7 xx0127445
- 700 1_
- $a Vícha, Aleš, $d 1971- $7 xx0116880
- 700 1_
- $a Eckschlager, Tomáš, $d 1956- $7 jn20000400613
- 773 0_
- $t Cancer Genetics & Cytogenetics $w MED00001039 $g Roč. 196, č. 1 (2010), s. 96-104
- 910 __
- $a ABA008 $b x $y 2
- 990 __
- $a 20110801122106 $b ABA008
- 991 __
- $a 20121102095246 $b ABA008
- 999 __
- $a ok $b bmc $g 881685 $s 732206
- BAS __
- $a 3
- BMC __
- $a 2010 $x MED00001039 $b 196 $c 1 $d 96-104 $m Cancer genetics and cytogenetics $n Cancer Genet Cytogenet
- LZP __
- $a 2011-4B09/jvme